Drug profile · INN
mecasermin
INCRELEX
mecasermin (INCRELEX) is a insulin-like growth factor i receptor agonist. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Systemic hormonal preparations (H01) H01AC03
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — mecasermin
- Class
- Systemic hormonal preparations (H01)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
mecasermin (INCRELEX) is a insulin-like growth factor i receptor agonist. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN mecasermin
Brand INCRELEX
Mechanism Insulin-like growth factor I receptor agonist
Target Insulin-like growth factor 1 receptor
Therapeutic class Systemic hormonal preparations (H01)
ATC code H01AC03
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Insulin-like growth factor I receptor agonist
Primary target: Insulin-like growth factor 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mecasermin?
mecasermin (INCRELEX) is a insulin-like growth factor i receptor agonist. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for mecasermin?
INCRELEX is a marketed brand name for mecasermin. Check FDA Drugs@FDA for the current US label holder and prescribing information.